Paying attention to the website and the pipeline, It seems we could get winlevi the next year, as It has almost completed phase III.
It contains only 1% of the product, but in the studies there were changes from baseline (56% with only 2,5%; 58% with 5% and 62% with 7,5%).
Perhaps It could be a good addition until 2022, as it would be a local (moderate) antiandrogen and anti-inflammatory (this last one is really important, as It would attack PGD2): we might get like 40% change form baseline and stop most of further loss.
Should we be optimistic?